Sangretech Biomedical and Bostwick Laboratories Announce Amended License for Sangretech's Dendritic Cell Technology

Published: Oct 15, 2009

SEATTLE--(BUSINESS WIRE)--Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech’s dendritic cell technology in certain territories.

Back to news